ArticleOncology reports2022

Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells.

Yusuke Murase et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.